Extended Data Fig. 10: CD4+T cells are not required to induce CD8+ phenotypic and clonal repertoire shift after checkpoint blockade.
From: Inhibitory PD-1 axis maintains high-avidity stem-like CD8+ T cells
a, Representative flow cytometry plots of OVA-tetramer+ CD8+ T cells from Day 12 tdLN of mice pre-treated with or without anti-CD4 depleting antibodies, and with control IgG or anti-PD-L1/PD-L2 according to Fig. 5a experimental scheme. b, c, Mean fluorescence intensity of TCF-1 (b) and SLAMF6 (c) of OVA-tetramer+ TCF-1+ TSL normalized to naïve (CD44- TCF-1+ PD-1-) CD8+ T cells. d, e, Quantification of OVA-tetramer+ SLAMF6+ TSL from Day 12 tdLN (d) and re-scaled for each group (non-depleted and CD4-depleted) to show the relative extent of SLAMF6+ TSL reduction after checkpoint treatment (e). f, g, Standardized log transformed imputed TCR affinity index (f) and mean imputed affinity index (g) of each treatment group, normalized to non-CD4-depleted, IgG-treated SLAMF6+ TSL from the same experimental cohort. Each data point represents the mean subset value from each animal. h, Tumour volume measured at the experimental end point at Day 12. Data from 3 independent experiments (n = 9 for non-depleted IgG and aPD-L1/2; n = 6 for CD4-depleted IgG; n = 10 for CD4-depleted aPD-L1/2). Error bars: means ± s.d. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; unpaired two-tailed t-test in (e), one-way ANOVA with Tukey’s multiple comparisons in all others.
